A joint research by two top drug-makers in the world, Bristol-Myers Squibb Co and AstraZeneca PLC, has developed a new type of treatment for advanced Type 2 diabetes, reported reuters.com. In the lab the new drug is also known as dapagliflozin.
At a scientific meeting in Orlando this weekend for the American Diabetes Association, researchers from the two top drug-makers show the new drug could control weight loss and reduce insulin dose to diabetes patients. The main mode of action from the new drug is that it could block sodium-glucose transporter-2 inhibitors.
Comments